Sanofi
Dupixent
chronic spontaneous urticaria
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews Dupixent for chronic spontaneous urticaria around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 11h ago
“A final decision is expected in the coming months.”